HHS Secretary renews public health emergency declaration on opioid crisis

19 March 2025

Newly-appointed US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has renewed the public health emergency declaration addressing the USA’s opioid crisis, which will allow sustained federal coordination efforts and preserve key flexibilities that enable HHS to continue leveraging expanded authorities to conduct certain activities in response to the opioid overdose crisis.

“Although overdose deaths are starting to decline, opioid-involved overdoses remain the leading cause of drug-related fatalities,” HHS Secretary Kennedy said. “This Administration is going to treat this urgent crisis in American health as the national security emergency that it is. Renewing the Opioid Public Health Emergency Declaration affirms the Administration’s commitment to addressing the opioid overdose crisis and is one of many critical steps we will take to Make America Healthy Again,” he added.

The public health emergency, first declared under President Trump’s leadership in 2017, was set to expire on March 21, 2025. Today’s renewal extends the emergency for 90 days.  The declaration of a public health emergency provides the Secretary with certain authorities necessary to respond to the emergency. The Department has relied on this declaration to facilitate voluntary information collections, expedite demonstration projects related to substance use disorder treatment, and expedite support for research on opioid use disorder treatments. These activities facilitate multi-level coordination across the public and private sector alike, which ultimately, will continue to save lives.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical